semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Covid19 Patient with clinical symptomatology suspecting COVID-19, that is to say: severe dyspnea, and/or serious extra pulmonary signs (myalgia, diarrhea, etc.) OR Patient with clinical symptomatology (cough or dyspnea or fever with ENT signs) AND at least one of the following comorbidities: COPD stage 1 or 2 (dyspnea usually absent or for marked efforts), Asthma with daily inhaled corticosteroid therapy, Immunosuppression or cancer during chemotherapy, Coronary history, Heart failure (Stages 2 and 3, dyspnea with moderate or low effort), Obesity (BMI> 30), Type 1 or 2 diabetes, cirrhosis from Child B, pregnant woman in the 3rd trimester Patient with a phone monitoring of at least more than 2 calls, if no aggravation of disease  Person deprived of liberty by judicial or administrative decision Person being subject to a legal protection measure Person who expressed opposition to participating in the study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID-19 Acute Respiratory Failure Adult (≥18 years old) at the time of consent 2. Positive COVID-19 test result or highly suspicious for COVID-19 infection and have a test pending 3. Acute Respiratory Failure (new requirement for supplemental oxygen or acute increase in required supplemental oxygen)  Expected death or withdrawal of life-sustaining treatments within 3 days 2. Unable to walk ≥150 feet prior to COVID-19 (due to 6-minute walk test being primary outcome for in-person testing) 3. Hemoglobin ≤7.0 at the time of consent 4. Pre-existing cognitive/language impairment prohibiting clinical outcomes assessment 5. Prior lung resection (due to spirometry as part of in-person outcome assessment) 6. Unable to provide consent and no legally authorized representative (LAR) identified or reached by phone 7. Pregnant 8. Incarcerated 9. Homelessness 10. Physician declines patient enrollment (attending physician or study physician) 11. Patient or LAR do not consent to participate in the study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID Corona Virus Infection COVID19 The patient or legally authorized representative (LAR) must have the ability to understand and the willingness to provide a signed and dated informed consent form. 2. Age 18 years and over 3. The patient agrees to use adequate contraception for the duration of the treatment protocol and for 6 months post treatment. 4. Positive RT PCR testing for COVID-19 nucleic acid using nasopharyngeal swabbing or any other site 5. Patient meets ARDS as defined by Berlin and is on mechanical ventilation a. Berlin for ARDS are: i. bilateral opacities on chest imaging consistent with pulmonary edema ii. A need for positive pressure ventilation via endotracheal or tracheostomy tube iii. PaO2/FiO2 ratio ≤ 300mmHg with a minimum of 5 cmH20 PEEP iv. Infiltrates not fully explained by cardiac failure or fluid overload in the physician's best clinical judgement ARDS onset is considered the time that the last of 1-4 is met. Infiltrates considered "consistent with pulmonary edema" any infiltrate not due to mass, atelectasis, or effusion, or opacities known to be chronic (greater than 1 week old). Vascular redistribution or indistinct vessels or heart border alone do not qualify as opacities  Evidence of multiorgan failure involving one or more organs, excluding the lungs as defined below: 1. Presence of shock, defined as MAP < 65 mmHg with signs of peripheral hypoperfusion, or continuous infusion of 2 or more vasopressor or inotrope agents to maintain MAP ≥ 65 mmHg. 2. Serum bilirubin > 10 mg/dl 3. Platelet count < 50,000/ml 2. Evidence of acquired or congenital immunodeficiency (due to immunosuppressive therapy, HIV, previous treatment for cancer, etc.) 3. History of metastatic cancer in the past 3 years 4. History of previous treatments with MSCs or other cell therapies 5. Patient is co-enrolled in any other IND-sponsored clinical trials for COVID-19 6. Evidence of pregnancy or lactation 7. Moribund patient not expected to survive > 24 hours 8. Unable/unwilling to deliver lung protective ventilation 9. Patient is receiving Extracorporeal Membrane Oxygenation (ECMO)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Covid19 Convalescence Respiratory rate > 30 breaths/min; PLUS 2. Severe respiratory distress; or SpO2 ≤ 88% on room air or PaO2/FiO2≤ 300 mm of Hg, PLUS 3. Radiological evidence of bilateral lung infiltrate, AND OR 4. Systolic BP < 90 mm of Hg or diastolic BP <60 mm of Hg. AND OR 5. 1 to 4 AND or patient in Ventilator support  Patients below18 years. 2. Pregnant women and breast-feeding mothers. 3. Previous history of allergic reaction to plasma 4. Those who will not give consent
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 19.0-99.0,  Hypertension Able to provide signed and dated informed consent form Persistant arterial hypertension with systolic blood pressure above 150 mmHg during hospitalisation and the day of randomisation Stable anti-hypertensive medication with at least two guideline-recommended anti-hypertensive drugs  Systolic blood pressure ≥180mmHg on the day of randomisation Spermidine intolerance Significant renal impairment defined as glomerular filtration rate < 45ml/min Insulin-dependent diabetes mellitus (IDDM) Wheat allergy or gluten intolerance Life expectancy of less than 12 months Participation in another clinical trial
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  COVID-19 SARS-CoV-2 Infection Previous laboratory confirmation of SARS-Cov-2 infection defined as a positive result of reverse polymerase-transcriptase chain reaction test in real-time of a sample taken by nasal and/or pharyngeal swab; and Severe pneumonia defined by the presence of fever or suspected lower respiratory infection, plus one of the following respiratory rate> 30 movements/min; severe respiratory distress; SpO2≤93% in room air; or pulmonary infiltrates>50% on chest imaging within 24-48hrs of acute symptoms onset; and/or Acute respiratory distress syndrome (ARDS) defined according to COVID-19 operational management guide of World Health Organization and classified as mild (200 mmHg <PaO2 / FiO2 ≤ 300 mmHg), moderate (100 mmHg <PaO2 / FiO2 ≤ 200 mmHg) or severe (PaO2 / FiO2 ≤ 100 mmHg). When the PaO2 is not available, SpO2 / FiO2 ≤ 315 suggests ARDS  Lack of clinical stability for 2 months before (including those who remain hospitalized) Active respiratory tract infection (of any cause); or Any clinical condition that prevents the performance of the study procedures
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.083-999.0,  Coronavirus Coronavirus Infection Covid19 Sars-CoV2 Population 1  Children of priority staff welcomed in the crèche during the period of confinement, i.e. from 15 March to 9 May, regardless of the length of time they are in the crèche during this period and their "symptomatic or not" status during this period or on the day of inclusion Consent of the holders of parental authority Affiliated to a social security system or entitled person Population 2  Nursery staff, regardless of their status/occupation and having had contact with the children during the period of confinement regardless of how long they have been in the nursery during this period and their "symptomatic or not" status during this period or on the day of inclusion Consent to participate Affiliated to a social security system or entitled person Population 3  Hospital staff not exposed to patients and/or children, with or without children in day care, working in the bacteriology, biochemistry and biological haematology laboratories or in an administrative department of the participating hospitals Affiliated to a social security system or entitled person  Population 1  Refusal to sign consent by parents Clinical condition requiring urgent medical assessment (attending physician or transfer to paediatric emergency) Population 2 and 3  Refusal to sign consent for staff Clinical condition requiring urgent medical evaluation
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  COVID-19 Hospitalized with coronavirus (SARS-CoV-2) infection, confirmed by polymerase chain reaction (PCR) test or other commercial or public health assay in any specimen, as documented by either of the following PCR positive in sample collected <72 hours prior to randomization; OR PCR positive in sample collected ≥72 hours prior to randomization (but no more than 14 days prior to randomization), documented inability to obtain a repeat sample (for example, due to lack of testing supplies, limited testing capacity, results taking >24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection Requires supplemental oxygen at the time of study entry and at randomization Have indicators of risk of progression: at least 1 inflammatory markers >upper limit of normal (ULN) (C reactive protein [CRP], D dimer, lactate dehydrogenase [LDH], ferritin) with at least 1 instance of elevation >ULN within 2 days before study entry  Are receiving cytotoxic or biologic treatments (such as tumor necrosis factor [TNF] inhibitors, anti-interleukin-1 [IL-1], anti-IL-6 [tocilizumab or sarilumab], T-cell or B-cell targeted therapies (rituximab), interferon, or Janus kinase (JAK) inhibitors for any indication at study entry. Note: A washout period 4 weeks (or 5 half-lives, whichever is longer) is required prior to screening Have ever received convalescent plasma or intravenous immunoglobulin [IVIg]) for COVID-19 Have received high dose corticosteroids at doses >20 mg per day (or prednisone equivalent) administered for ≥14 consecutive days in the month prior to study entry Strong inhibitors of OAT3 (such as probenecid) that cannot be discontinued at study entry Have received neutralizing antibodies, such as bamlanivimab, casirivimab and imdevimab for COVID-19 Have diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by history only, no screening tests required) Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking investigational product Have received any live vaccine within 4 weeks before screening, or intend to receive a live vaccine during the study. Note: Use of nonlive (inactivated) vaccinations is allowed for all participants Require invasive mechanical ventilation, including extracorporeal membrane oxygenation (ECMO) at study entry Current diagnosis of active malignancy that, in the opinion of the investigator, could constitute a risk when taking investigational product
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Contraception Women 18 years and older currently using COCs or who have a COC prescription and are intending to initiate COCs for contraception  Women who have contraindications to using a COC or a contraceptive implant (Category 3 or 4 in the CDC Medical [MEC]) Because the CDC MEC are continuously revised, the most updated will be used (http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5904a3.htm) Women who are currently participating in a clinical trial or have participated within the past 30 days Less than 2 weeks from the end of a pregnancy
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Spontaneous Urticaria Patients with active CSU for at least 4 months which was treated with anti-histamines as well as at least one course of steroids (ex. Prednisone) Age ≥18 years Patients will undergo an ECG and QT parameters will be measured for further analysis Female subjects who are postmenopausal (absence of menses for ≥ 2 years confirmed by a follicle stimulating hormone test), or who are surgically sterilized may be enrolled. Similarly, women of childbearing potential who had a negative pregnancy test at screening, who are willing to use two medically acceptable methods of contraception for the duration of the study as well as for at least three months after cessation of CBD treatment and who are willing to undergo pregnancy testing according to the study protocol may be enrolled Female subjects who are not breast-feeding and who have no intention to breast-feed during the term of the trial and for at least three months after cessation of CBD treatment may be enrolled Subject able to provide written informed consent  Viral Hepatitis (HAV, HBV, HCV) HIV Serious psychiatric or psychological disorders Other chronic dermatological conditions under active treatment Active consumption of illicit drugs including cannabis or derivatives for at least three months prior to the study Patients with significant cardiac, respiratory or active malignance disease (except Basel Cell Carcinoma) comorbidities Any uncontrolled infection at time of registration Renal comorbidity: eGFR < 30 mL/min/1.73m2 (note: CKD Grade 4 is defined as eGFR 15-29 mL/min/1.73 m2) Patient who is taking immunomodulatory medications for other indication Women of child-bearing potential who intend to become pregnant or who are pregnant or breastfeeding
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  COVID-19 Pneumonia confirmed COVID-19 infection (diagnosed by nasopharyngeal swab performed on admission) severe pneumonia with baseline chest X-ray abnormalities Oxygen saturation <94% on room air, and tachypnea with respiratory rate exceeding 30 per minute Informed consent signed  Not willing to participate in the study
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  COVID-19 SARS-CoV 2 ARDS, Human Immune System Disorder All patients ≥16 years old with confirmation of COVID-19 2. All patients ≥ 16 years old with chronic lung disease (CF, non-CF bronchiectasis, asthma, COPD or Idiopathic Pulmonary Fibrosis) or with no evidence of prior chronic lung disease 3. Healthy volunteers  None
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Covid19 Chronic Inflammation Non-Communicable Chronic Diseases Patients (18 -80 years) with mild to moderate COVID-19 cases consented to home or hospital isolation to follow them  Severe cases not fulfilling the definition of mild and moderate cases. Definition of mild cases according to The Egyptian Ministry Of Health: (MOH) 1. Age < 60 2. Temperature <38.5 3. SaO2 >92% 4. Heart Rate <110 5. Respiratory Rate <25 /min. 6. Neutrophil / lymphocyte ratio on CBC < 3.1 7. No co-morbidities that necessitates hospital admission: Pregnancy, severe uncontrolled Diabetes, Chronic lung disease, Chronic kidney disease, Chronic liver disease, Serious heart diseases (arrythmia, Ischemic heart disease, uncontrolled hypertension), immunocompromised: prolonged use of corticosteroids and other immunosuppressive drugs/ organ transplantation/ HIV/ Immunodeficiency, Obesity (BMI > 40) Any patient not fulfilling the above mild is considered having moderate disease as well as any positive pulmonary imaging findings
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Exacerbation Participant is willing and able to give informed consent for participation in the trial Male or Female, aged 40 years or above Diagnosed with COPD (primary or secondary care diagnosis) with spirometric confirmation of airflow obstruction (FEV1/FVC ratio <0.7) A history of at least 1 exacerbation in the previous 12 months, requiring systemic corticosteroids and/or antibiotics Current or ex-smoker with at least a 10 pack year smoking history In the opinion of the research staff, is able and willing to comply with all trial requirements  History of atopic childhood asthma Current history of primary lung malignancy or current active pulmonary TB Clinically relevant disease or disorder (past or present) which in the opinion of the investigator may either put the subject at risk because of participating in the study or may influence the results of the study or the subject's ability to participate in the study Any clinically relevant lung disease, other than COPD considered by the investigator to be the primary diagnosis. For example mild-to-moderate bronchiectasis is acceptable in addition to COPD unless the bronchiectasis is considered to be the primary diagnosis An alternative cause for the increase in symptoms of COPD that are unrelated to an exacerbation such as i) suspicion or clinical evidence of pneumonia; ii) high probability and suspicion of pulmonary embolism; iii) suspicion or clinical evidence of a pneumothorax; iv) primary ischaemic event ST or Non ST elevation myocardial infarct and left ventricular failure [i.e. not an exacerbation of COPD] A known allergy to the IMP (prednisolone), NIMP (doxycycline) or to any of the constituents of the placebo Patients on maintenance corticosteroids (prednisolone, hydrocortisone, fludrocortisone) Known adrenal insufficiency Currently enrolled in another CTIMP trial and receiving an intervention as part of the trial
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  COVID19 Coronavirus Infection Pregnancy Disease Severe Acute Respiratory Syndrome Pregnant or puerperal women Diagnosis of flu syndrome on admission Testing for COVID-19 performed  Clinical impossibility of signing the Informed Consent Form (ICF), either by the patient or guardian (in the prospective arm) Incomplete or not located medical records (retrospective arm)